Risk stratification after myocardial infarction

Annals of Internal Medicine

Volumn 126, Issue 7, 1997, Pages 561-582

  Peterson, Eric D ^a   Shaw, Leslee J ^a   Califf, Robert M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; CORONARY REPERFUSION; CORONARY RISK; COST CONTROL; ELECTROCARDIOGRAPHY; EXERCISE TEST; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HIGH RISK POPULATION; HOSPITALIZATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; TREATMENT PLANNING;

EID: 0030902597     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-126-7-199704010-00012     Document Type: Review

References (280)

1. DeBusk RF. Specialized testing after recent acute myocardial infarction. Ann Intern Med. 1989;110:470-81.
2. Kleiman NS, White HD, Ohman EM, Ross AM, Woodlief LH, Califf RM, et al. Mortality within 24 hours of thrombolysis for myocardial infarction. The importance of early reperfusion. The GUSTO Investigators, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. Circulation. 1994;90:2658-65.
3. Cragg DR, Friedman HZ, Bonema JD, Jaiyesimi IS, Ramos RG, Timmis GC, et al. Outcome of patients with acute myocardial infarction who are ineligible for thrombolytic therapy. Ann Intern Med. 1991;115:173-7.
4. Althouse R, Maynard C, Cerqueira MD, Olsufka M, Ritchie JL, Kennedy JW. The Western Washington Myocardial Infarction Registry and Emergency Department Tissue Plasminogen Activator Treatment Trial. Am J Cardiol. 1990;66:1298-303.
5. Low KG, Joliceour MR, Colman RA, Stone LE, Fleisher CL. Women participants in research: assessing progress. Women Health. 1994;22:79-98.
6. Gurwitz JH, Gore JM, Goldberg RJ, Rubison M, Chandra N, Rogers WJ. Recent age-related trends in the use of thrombolytic therapy in patients who have had acute myocardial infarction. National Registry of Myocardial Infarction. Ann Intern Med. 1996;124:283-91.
7. Shaw L , Peterson ED, Kesler K, Hasselblad V, Califf RM. A metaanalysis of predischarge risk stratification after acute myocardial infarction with stress electrocardiographic, myocardial perfusion, and ventricular function imaging. Am J Cardiol. 1996;78:1327-37.
8. Roubin GS, Califf RM, O'Neill WW, Phillips HR 3d, Stack RS, eds. Interventional Cardiovascular Medicine: Principles and Practice. New York: Churchill Livingslone; 1994.
9. Braunwald E, ed. Heart Disease: A Textbook of Cardiovascular Medicine. 4th ed. Philadelphia: WB Saunders; 1992.
10. Califf RM, Mark DB, Wagner GS, eds. Acute Coronary Care. 2d ed. St. Louis, MO: Mosby-Year Book; 1995.
11. Eddy DM, Hasselblad V, Shachter R. An introduction to a Bayesian method for meta-analysis: the confidence profile method. Med Decis Making. 1990;10:15-23.
12. Morris RM, Barnaby PF, Brandt PW, Geary GG, Whitlock RM, Wild CJ, et al. Prognosis after recovery from first acute myocardial infarction: determinants of reinfarction and sudden death. Am J Cardiol. 1984;53:408-13.
13. Henning H, Gilpin EA, Covell JW, Swan EA, O'Rourke RA, Ross J Jr. Prognosis after acute myocardial infarction: a multivariate analysis of mortality and survival. Circulation. 1979;59:1124-36.
14. Dubois C, Pierard LA, Albert A, Smeets JP, Demoulin JC, Boland J, et al. Short-term risk stratification at admission based on simple clinical data in acute myocardial infarction. Am J Cardiol. 1988;61:216-9.
15. Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction. TIMI II A results. The TIMI Research Group. JAMA. 1988;260:2849-58.
16. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. The International Study Group. Lancet. 1990;336: 71-5.
17. Lee KL, Woodtief LH, Topol EJ, Weaver WD, Betriu A, Col J, et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-1 Investigators. Circulation. 1995;91:1659-68.
18. Norris RM, Brandt PW, Caughey DE, Lee AJ, Scott PJ. A new coronary prognostic index. Lancet. 1969;1:274-8.
19. Fallen EL, Armstrong P, Cairns J, Dafoe W, Frasure-Smith N, Langer A, et al. Report of the Canadian Cardiovascular Society's consensus conference on Management of the Postmyocardial Infarction Patient. Can Med Assoc J. 1991;144:1015-25.
20. Madsen EB, Gilpin E, Henning H. Short-term prognosis in acute myocardial infarction: evaluation of different prediction methods. Am Heart J. 1984; 107:1241-51
21. Mukharji J, Rude RE, Poole WK, Gustafson N, Thomas LJ Jr, Strauss HW, et al. Risk factors for sudden death after acute myocardial infarction: two-year follow-up. Am J Cardiol. 1984;54:31-6.
22. Selker HP, Griffith JL, D'Agostino RB. A time-insensitive predictive instrument for acute myocardial infarction ortality: a multicenter study. Med Care. 1991;29:1196-211.
23. White HD, Barbash Gl, Califf RM, Simes RJ, Granger CB, Weaver WD, et al. Age and outcome with contemporary thrombolytic therapy: results from the GUSTO-1 trial. Circulation. 1996;94:1826-33.
24. Goldberg RJ, Gore JM, Gurwitz JH, Alpert JS, Brady P, Strohsnitter W, et al. The impact of age on the incidence and prognosis of initial acute myocardial infarction: the Worcester Heart Attack Study. Am Heart J. 1989; 117:543-9.
25. Weaver WD, White HD, Wilcox RG, Aylward PE, Morris D, Guerci A, et al. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I Investigators JAMA. 1996;275:777-82.
26. Vaccarino V, Krumholz HM, Berkman LF, Horwitz Rl. Sex differences in mortality after myocardial infarction. Is there evidence for an increased risk for women? Circulation 1995;91:1861-71.
27. Fiebach NH, Viscoli CM, Horwitz Rl. Differences between women and men in survival after myocardial infarction. Biology or methodology? JAMA. 1990;263:1092-6.
28. Dittrich H, Gilpin E, Nicod P, Call G, Henning H, Ross J Jr. Acute myocardial infarction in women: influence of gender on mortality and prognostic variables. Am J Cardiol. 1988;62:1-7.
29. Lincoff AM, Califf RM, Ellis SG, Sigmon KN, Lee KL, Topol EJ. Thrombolytic therapy for women with myocardial infarction: is there a gender gap? Thrombolysis and Angioplasty in Myocardial Infarction Study Group. J Am Coll Cardiol. 1993;22:1780-7.
30. Becker RC, Terrin M, Ross R, Knatterud GL, Desvigne-Nickens P, Gore JM, et al. Comparison of clinical outcomes for women and men after acute myocardial infarction. The Thrombolysis in Myocardial Infarction Investigators. Ann Intern Med. 1994;120:638-45.
31. Tofler GH, Stone PH, Muller JE, Willich SN, Davis VG, Poole WK, et al. Effects of gender and race on prognosis after myocardial infarction: adverse prognosis for women, particularly black women. J Am Coll Cardiol. 1987;9:473-82.
32. Greenland P, Reicher-Reiss H, Goldbourt U, Behar S. In-hospital and 1-year mortality in 1,524 women after myocardial infarction. Comparison with 4,315 men. Circulation. 1991;83:484-91.
33. Barbash Gl, Reiner J, White HD, Wilcox RG, Armstrong PW, Sadowski Z, et al. Evaluation of the paradoxic beneficial effects of smoking in patients receiving thrornbolytic therapy for acute myocardial infarction: mechanism of the "smoker's paradox" from the GUSTO-I trial, with angiographic insights. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol. 1995;26:1222-9.
34. Grines CL, Topol EJ, O'Neill WW, George BS, Kereiakes D, Phillips HR, et al. Effect of cigarette smoking on outcome after thrornbolytic therapy for myocardial infarction. Circulation. 1995;91:298-303.
35. Forrester JS, Diamond G, Chatterjee K, Swan HJ. Medical therapy of acute myocardial infarction by application of hemodynamic subsets. N Engl J Med. 1976;295:1356-62.
36. Killip T 3d, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol. 1967;20: 457-64.
37. Effectiveness of intravenous thrornbolytic treatment in acute myocardial infarction. Gruppo italiano per lo Studio della Streptochinasi nell'lnfarto Miocardico (GISSI). Lancet. 1986;1:397-402.
38. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. The TIMI Study Group. N Engl J Med. 1989;320:618-27.
39. Zabel KM, Hathaway WR, Peterson ED, Granger CB, Armstrong PW, Morris D, et al. Baseline electrocardiogram predicts 30-day mortality among 32,812 patients with acute myocardtal infarction treated with thrombolysis [Abstract]. J Am Coll Cardiol. 1995;25:342A.
40. Bilbao FJ, Zabalza IE, Vilanova JR, Froufe J. Atrioventricutar block in posterior acute myocardial infarction: a clinicopathologic correlation. Circulation. 1987;75:733-6.
41. Clemmensen P, Ohman EM, Sevilla DC, Peck S, Wagner NB, Quigley PS, et al. Changes in standard electrocardiographic ST-segment elevation predictive of successful reperfusion in acute myocardial infarction. Am J Cardiol. 1990;66:1407-11.
42. Fisch GR, Zipes DP, Fisch C. Bundle branch block and sudden death. Prog Cardiovasc Dis. 1980;23:187-224.
43. Mavric Z, Zaputovic L, Matana A, Kucic J, Roje J, Marinovic D, et al. Prognostic significance of complete atrioventricular block in patients with acute inferior myocardial infarction with and without right ventricular involvement. Am Heart J. 1990;119:823-8.
44. Goldberg RJ, Seeley D, Becker RC, Brady P, Chen ZY, Osganian V, et al. Impact of atrial fibrillation on the in-hospital and long-term survival of patients with acute myocardial infarction: a community-wide perspective. Am Heart J. 1990;119:996-1001.
45. Bates ER, Clemmensen PM, Califf RM, Gorman LE, Aronson LG, George BS, et al. Precordial ST segment depression predicts a worse prognosis in inferior infarction despite reperfusion therapy. The Thrombolysis and Angiopiasty in Myocardial Infarction (TAMI) Study Group. J Am Coll Cardiol. 1990;16:1538-44.
46. Lembo NJ, Starling MR, Dell'ltalia LJ, Crawford MH, Chaudhuri TK, O'Rourke RA. Clinical and prognostic importance of persistent precordial (V1-V4) electrocardiographic ST segment depression in patients with inferior transmural myocardial infarction. Circulation. 1986;74:56-63.
47. Peterson ED, Hathaway WR, Zabel KM, Pieper KS, Granger CB, Wagner GS, et al. Prognostic significance of precordial ST segment depression during inferior myocardial infarction in the thrornbolytic era: results in 16,521 patients. J Am Coll Cardiol. 1996;28:305-12
48. Zehender M, Kasper W, Kauder E, Schonthaler M, Geibel A, Olschewski M, et al. Right ventricular infarction as an independent predictor of prognosis after acute inferior myocardial infarction. N Engl J Med. 1993; 218:981-8.
49. Lee TH, Goldman L. Serum enzyme assays in the diagnosis of acute myocardiai infarction. Recommendations based on a quantitative analysis. Ann Intern Med. 1986;105:221-33.
50. Lee TH, Weisberg MC, Cook EF, Daley K, Brand DA, Goldman L. Evaluation of creatme kinase and creatme kinase-MB for diagnosing myocardiai infarction. Clinical impact in the emergency room. Arch Intern Med. 1987;147:115-21.
51. Katus HA, Remppis A, Scheffold T, Diederich KW. Intracellular compartmentation of cardiac troponin T and its release kinetics in patients with reperfused and nonreperfused myocardiai infarction Am J Cardiol. 1991;67: 1360-7.
52. Adams JE 3d, Bodor GS, Davila-Roman VG, Delmez JA, Apple FS, Ladenson JH, et al. Cardiac troponin I. A marker with high specificity for cardiac injury Circulation. 1993;88:101-6.
53. Wagner I, Mair J, Fridrich L, Artner-Dworzak E, Lechleitner P, Morass B, et al. Cardiac troponin T release in acute myocardial infarction is associated with scintigraphic estimates of myocardial scar. Coron Artery Dis. 1993, 4:537-44
54. Ohman EM, Armstrong PW, Christenson RH, Granger CB, Katus HA, Hamm CW, et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO HA Investigators. N Engl J Med. 1996;335: 1333-41.
55. Remppis A, Scheffold T, Karrer O, Zehelein J, Hamm C, Grunig E, et al. Assessment of reperfusion of the infarct zone after acute myocardial infarction by serial cardiac troponin T measurements in serum. Br Heart J. 1994;71:242-8.
56. Abe S, Arima S, Yamashita T, Miyata M, Okino H, Toda H, et al. Early assessment of reperfusion therapy using cardiac troponin T. J Am Coll Cardiol. 1994;23:1382-9.
57. Pellikka PA, Behrenbeck T, Verani MS, Mahmarian JJ, Wackers FJ, Gibbons RJ. Serial changes in myocardial perfusion using tomographic technetium-99m-hexakis-2-methoxy-2-methylpropyl-isonitrile imaging following reperfusion therapy of myocardial infarction. J Nucl Med. 1990;31:1269-75.
58. Wackers FJ, Terrin ML, Kayden OS, Knatterud G, Forman S, Braunwald E, et al. Quantitative radionuclide assessment of regional ventricular function after thrombolytic therapy for acute myocardial infarction: results of phase I Thrombolysis in Myocardial Infarction (TIMI) trial. J Am Coll Cardiol. 1989;13:998-1005.
59. McCallister BD Jr, Christian TF, Gersh BJ, Gibbons RJ. Prognosis of myocardial infarctions involving more than 40% of the left ventricle after acute reperfusion therapy. Circulation. 1993;88(4 Pt 1):1470-5.
60. Gibbons RJ, Verani MS, Behrenbeck T, Pellikka PA, O'Connor MK, Mahmarian JJ, et al. Feasibility of tomographic 99mTc-hexakis-2-methoxy-2-methylpropyl-isonitrile imaging for the assessment of myocardial area at risk and the effect of treatment in acute myocardial infarction. Circulation. 1989;80:1277-86.
61. Christian TF, Schwarte RS, Gibbons RJ. Determinants of infarct size in reperfusion therapy for acute myocardial infarction. Circulation. 1992;86:81-90.
62. Lomboy CT, Schulman DS, Grill HP, Flores AR, Orie JE, Granato JE. Rest-redistribution thallium-201 scintigraphy to determine myocardial viability early after myocardial infarction. J Am Coll Cardiol. 1995;25:210-7.
63. Cornel JH, Arnese M, Forster T, Postma-Tjoa J, Reijs AE, Fioretti PM. Potential and limitations of Tc-99m sestamibi scintigraphy for the diagnosis of myocardial viability. Herz. 1994;19:19-27.
64. Corbett JR, Lewis SE, Wolfe CL, Jansen DE, Lewis M, Relias JS, et al. Measurement of myocardial infarct size by technetium pyrophosphate single-photon tomography. Am J Cardiol. 1984;54:1231-6.
65. Tamaki S, Kadota K, Kambara H, Suzuki Y, Nohara R, Murakami T, et al. Emission computed tomography with technetium-99m pyrophosphate for delineating location and size of acute myocardial infarction in man. Br Heart J. 1984;52:30-7.
66. Huber KC, Bresnahan JF, Bresnahan DR, Pellikka PA, Behrenbeck T, Gibbons RJ. Measurement of myocardium at risk by technetium-99m sestamibi: correlation with coronary angiography. J Am Coll Cardiol. 1992;19: 67-73.
67. De Coster PM, Wijns W, Cauwe F, Robert A, Beckers C, Melin JA. Area-at-risk determination by technetium-99m-hexakis-2-methoxyisobutyl isonitrile in experimental reperfused myocardial infarction. Circulation. 1990; 82:2152-62.
68. Macieira-Coelho E, Cantinho G, da Costa BB, Garcia-Alves M, Lacerda AP, Dionisio l, et al. Minimal residual coronary obstructions in patients who suffered a first myocardial infarction. A prospective study comparing coronary angiography and exercise thallium scintigraphy. Clin Cardiol. 1993; 16:879-82.
69. Fletcher WO, Gibbons RJ, Clements IP. The relationship of inferior ST depression, lateral ST elevation, and left precordial ST elevation to myocardium at risk in acute anterior myocardial infarction. Am Heart J. 1993;126(3 Pt 1):526-35.
70. Christian TF, Clements IP, Behrenbeck T, Huber KC, Chesebro JH, Gersh BJ, et al. Limitations of the electrocardiogram in estimating infarction size after acute reperfusion therapy for myocardial infarction. Ann Intern Med. 1991;114:264-70.
71. Silverman KJ, Becker LC, Bulkley BH, Burow RD, Mellits ED, Kallman CH, et al. Value of early thallium-201 scintigraphy for predicting mortality in patients with acute myocardial infarction. Circulation. 1980;61:996-1003.
72. Gibson WS, Christian TF, Pellikka PA, Behrenbeck T, Gibbons RJ. Serial tomographic imaging with technetium-99m-sestamibi for the assessment of infarct-related arterial patency following reperfusion therapy. J Nucl Med. 1992;33:2080-5.
73. Cerqueira MD, Maynard C, Ritchie JL, Davis KB, Kennedy JW. Long-term survival in 618 patients from the Western Washington Streptokinase in Myocardial Infarction trials. J Am Coll Cardiol. 1992;20:1452-9.
74. Niemeyer MG, Van der Wall EE, Pauwels EK, van Dijkman PR, Blokland JA, de Roos A, et al. Assessment of acute myocardial infarction by nuclear imaging techniques. Angiology. 1992;43:720-33.
75. Shimada T, Tsuda N, Kamihata H, Suga Y, Kurimoto T, Iwasaka T, et al. Quantification of infarct size by thallium-201 single-photon emission computed tomography using the unfolded map method. Comparison with QRS score and angiographic infarct size at 4 weeks after infarction. Clin Cardiol. 1994;17:184-90.
76. Howarth D, Coote D. "Window on the heart" technique for diagnosis of recent myocardial infarction using Tc-99m pyrophosphate SPECT subtraction imaging. Clin Nucl Med 1995;20:1-4
77. Bostrom PA, Diemer H, Freitag M, Juhlin P, Lilja B, Erhardt L. Myocardial reperfusion in thrombolysis A 99Tcm-Sestamibi SPECT study in patients with acute myocardial infarction. Clin Physiol. 1992;12:679-84.
78. Walamies M, Virtanen V, Koskinen M, Uusitalo A. Patency of the infarct-related coronary artery - a pertinent factor in late recovery of myocardial fatty acid metabolism among patients receiving thrombolytic therapy? Eur J Nud Med. 1994;21:968-72.
79. Sridhara BS, Dudzic E, Basu S, Senior R, Lahiri A. Reverse redistribution of thallium-201 represents a low-risk finding in thrombolysed patients following myocardial infarction. Eur J Nud Med. 1994;21:1094-7.
80. Christian TF, Clements IP, Gibbons RJ. Noninvasive identification of myocardium at risk in patients with acute myocardial infarction and nondiagnostic electrocardiograms with technetium-99m-Sestamibi. Circulation. 1991; 83:1615-20.
81. St. John Sutton M, Pfeffer MA, Plappert T, Rouleau JL, Moye LA, Dagenais GR, et al. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopnl. Circulation. 1994; 89:68-75.
82. Sabia P, Abbott RD, Afrookteh A, Keller MW, Touchstone DA, Kaul S. Importance of two-dimensional echocardiographic assessment of left ventricular systolic function in patients presenting to the emergency room with cardiac-related symptoms. Circulation. 1991;84:1615-24.
83. Nishimura RA, Tajik AJ, Shub C, Miller FA Jr, llstrup DM, Harrison CE. Role of two-dimensional echocardiography in the prediction of in-hospital complications after acute myocardial infarction. J Am Coll Cardiol. 1984;4: 1080-7.
84. Berning J, Launbjerg J, Appleyard M. Echocardiographic algorithms for admission and predischarge prediction of mortality in acute myocardial infarction. Am J Cardiol. 1992;69:1538-44.
85. Kan G, Visser CA, Koolen JJ, Dunning AJ. Short and long term predictive value of admission wall motion score in acute myocardial infarction. A cross sectional echocardiographic study of 345 patients. Br Heart J. 1986;56: 422-7.
86. Fleischmann KE, Goldman L, Robiolio PA, Lee RT, Johnson PA, Cook EF, et al. Echocardiographic correlates of survival in patients with chest pain. J Am Coll Cardiol. 1994;23:1390-6.
87. Bengtson JR, Kaplan AJ, Pieper KS, Wildermann NM, Mark DB, Pryor DB, et al. Prognosis in cardiogenic shock after acute myocardial infarction in the interventional era. J Am Coll Cardiol. 1992;20:1482-9.
88. Califf RM, Bengtson JR. Cardiogenic shock. N Engl J Med. 1994;330:1724-30.
89. Binder MJ, Ryan JA, Marcus S, Mugler F, Strange D, Agress CM. Evaluation of therapy in shock following acute myocardial infarction. Am J Med. 1985;18:622-32.
90. Hands ME, Rutherford JD, Muller JE, Davies G, Stone PH, Parker C, et al. The in-hospital development of cardiogenic shock after myocardial infarction: incidence, predictors of occurrence, outcome and prognostic factors. The MILIS Study Group. J Am Coll Cardiol. 1989;14:40-6.
91. Rackley CE, Russell RO Jr, Mantle JA, Rogers WJ. Cardiogenic shock. Cardiovasc Clin. 1981;11:15-24.
92. Scheldt S, Ascheim R, Kollip T 3d. Shock after acute myocardial infarction. A clinical and hemodynamic profile. Am J Cardiol. 1970;26:556-64.
93. Swan HJ, Forrester JS, Danzig R, Allen HN. Power failure in acute myocardiat infarction. Prog Cardiovasc Dis. 1970:12:568-600.
94. Robin ED. The cult of the Swan-Ganz catheter. Overuse and abuse of pulmonary flow catheters. Ann Intern Med. 1985;103:445-9.
95. Eisenberg PR, Jaffe AS, Schuster DP. Clinical evaluation compared to pulmonary artery catheterization in the hemodynamic assessment of critically ill patients. Crit Care Med. 1984;12:549-53.
96. Connors AF, Speroff T, Dawson NV, Thomas C, Harrell FE, Wagner D, et al. The effectiveness of right heart catheterization in the initial care of critically ill patients. JAMA. 1996;276:889-97.
97. Waksman R, Weiss AT, Gotsman MS, Hasin Y. Intra-aortic balloon counterpulsation improves survival in cardiogenic shock complicating acute myocardial infarction. Eur Heart J. 1993;14:71-4.
98. Indications for fibrinotytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet. 1994:343:311-22.
99. Bates ER, Topol EJ. Limitations of thrombolytic therapy for acute myocardial infarction complicated by congestive heart failure and cardiogenic shock. J Am Coll Cardiol. 1991:18:1077-84.
100. Meyer J, Merx W, Dorr R, Lambertz H, Bethge C, Effert S. Successful treatment of acute myocardial infarction shock by combined percutaneous transluminal coronary recanalization (PTCR) and percutaneous transluminal coronary angioplasty (PTCA). Am Heart J. 1982;103:132-4.
101. Holmes DR Jr, Bates ER, Kleiman NS, Sadowski Z, Morgan JH, Morris DC, et al. Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol. 1995;26:668-74.
102. Lee L, Bates ER, Pitt B, Walton JA, Laufer N, O'Neill WW. Percutaneous transluminal coronary angioplasty improves survival in acute myocardial infarction complicated by cardiogenic shock. Circulation. 1988;78:1345-51.
103. Sotolongo RP, Smith ML, Margolis WS. Coronary angioplasty in emergency treatment of myocardial infarction. Tex Heart Inst J. 1990;17:31-6.
104. O'Neill WW. Angioplasty therapy of cardiogenic shock: are randomized trials necessary? [Editorial] J Am Coll Cardiol. 1992;19:915-7.
105. Wall TC, Ohman EM, Califf RM. Reperfusion therapy: significance of recent trials to the practicing cardiologist. In: Anderson JL, ed. Modern Management of Acute Myocardial Infarction in the Community Hospital. New York: Marcel Dekker; 1991;103-18.
106. Stone GW, Grines CL, Browne KF, Marco J, Rothbaum D, O'Keefe J, et al. Predictors of in-hospital and 6-month outcome after acute myocardial infarction in the reperfusion era: the Primary Angioplasty in Myocardial Infarction (PAMI) trial. J Am Coll Cardiol. 1995;25:370-7.
107. de Boer MJ, Suryapranata H, Hoorntje JC Reiffers S, Liem AU Miedema K, et al. Limitation of infarct size and preservation of left ventricular function after primary coronary angioplasty compared with intravenous streptokinase in acute myocardial infarction. Circulation. 1994;90:753-61.
108. Gibbons RJ, Holmes DR, Reeder GS, Bailey KR, Hopfenspirger MR, Gersh BJ. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. The Mayo Coronary Care Unit and Catheterization Laboratory Groups. N Engl J Med. 1993;328:685-91.
109. Ferguson JJ. American College of Cardiology 45th Annual Scientific Session, Orlando, Florida, March 24 to 27, 1996. Circulation. 1996;94:1-5.
110. Brott T, Thalinger K, Hertzberg V. Hypertension as a risk factor for spontaneous intracerebral hemorrhage. Stroke. 1986;17:1078-83.
111. Krumholz HM. The clinical challenges of myocardial infarction in the elderly. West J Med. 1989;151:304-10.
112. Grines CL. Selection of patients for reperfusion therapy. In: Califf RM, Mark DB, Wagner GS, eds. Acute Coronary Care. 2d ed. St. Louis, MO: Mosby; 1995:215-28.
113. Bates ER. Reperfusion therapy in inferior myocardial infarction. J Am Coll Cardiol. 1988;12:44A-51A.
114. Grines CL, DeMaria AN, Optimal utilization of thrornbolytic therapy for acute myocardial infarction: concepts and controversies. J Am Coll Cardiol. 1990;16:223-31.
115. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) lib investigators. N Engl J Med. 1996;335:775-82.
116. Antman EM. Hirudin in acute myocardial infarction - thrombolysis and thrombin in myocardial infarction (TIMI) 9B trial. Circulation. 1996;94:911-21.
117. Braunwald E, Mark DB, Jones RH, Cheitlin MD. Fuster V, McCauley KM, et al. Unstable Angina: Diagnosis and Management. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, National Heart, Lung, and Blood Institute; 1994:1-154.
118. Lown B, Fakho AM, Hood WB Jr, Thorn GW. The coronary care unit. New perspectives and directions. JAMA. 1967; 199:188-98.
119. Goldman L. Coronary care units. A perspective on their epidemiologic impact. Int J Cardiol. 1982;2:284-7.
120. Lee TH, Juarez G, Cook EF, Weisberg MC, Rouan GW, Brand DA, et al. Ruling out acute myocardial infarction. A prospective multicenter validation of a 12-hour strategy for patients at low risk. N Engl J Med. 1991;324: 1239-46.
121. Gibler WB, Runyon JP, Levy RC, Sayre MR, Kacich R, Hattemer CR, et al. A rapid diagnostic and treatment center for patients with chest pain in the emergency department. Ann Emerg Med. 1995;25:1-8.
122. Gaspoz JM, Lee TH, Weinstein MC, Cook EF, Goldman P, Komaroff AL, et al. Cost-effectiveness of a new short-stay unit to "rule out" acute myocardial infarction in low risk patients. J Am Coll Cardiol. 1994;24:1249-59.
123. Barbagelata A, Granger CB, Topot EJ, Worley SJ, Kereiakes DJ, George BS, et al. Isolated recurrent ischemia after thrombolytic therapy: incidence, importance, and cost. Am J Cardiol. 1995;76:1007-13.
124. Betriu A, Heras M, Cohen M, Fuster V. Unstable angina: outcome according to clinical presentation. J Am Coll Cardiol. 1992;19:1659-63.
125. Ohman EM, Topol EJ, Califf RM, Bates ER, Ellis SG, Kereiakes DJ, et al. An analysis of the cause of early mortality after administration of thrornbolytic therapy. The Thrombolysis Angioplasty in Myocardial Infarction Study Group. Coron Artery Dis. 1993;4:957-64.
126. Roberts R, Rogers WJ, Mueller HS, Lambrew CT, Diver DJ, Smith HC, et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation. 1991;83:422-37.
127. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO Angiographic Investigators. N Engl J Med. 1993;329: 1615-22.
128. Kennedy JW, Ritchie JL, Davis KB, Stadius ML, Maynard C, Fritz JK. The western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. A 12-month follow-up report. N Engl J Med. 1985;312:1073-8
129. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group. N Engl J Med. 1985;312:932-6
130. Califf RM, O'Neil W, Stack RS, Aronson L, Mark DB, Mantell S, et al. Failure of simple clinical measurements to predict perfusion status after intravenous thrombolysis. Ann Intern Med. 1988;108:658-62.
131. Shah PK, Cercek B, Lew AS, Ganz W. Angiographic validation of bedside markers of reperfusion. J Am Coll Cardiol. 1993;21:55-61.
132. Schroder R, Dissmann R, Bruggemann T, Wegscheider K, Linderer T, Tebbe U, et al. Extent of early ST segment elevation resolution: a simple but strong predictor of outcome in patients with acute myocardial infarction. J Am Coll Cardiol. 1994;24:384-91.
133. Saran RK, Been M, Furniss SS, Hawkins T, Reid DS. Reduction in ST segment elevation after thrombolysis predicts either coronary reperfusion or preservation of left ventricular function. Br Heart J. 1990;64:113-7.
134. Richardson SG, Mortem P, Murtagh JG, Scon ME, O'Keeffe DB. Relation of coronary arterial patency and left ventricular function to electrocardiographic changes after streptokinase treatment during acute myocardial infarction. Am J Cardiol. 1988;61:961-5.
135. Hogg KJ, Hornung RS, Howie CA, Hockings N, Dunn FG, Hillis WS. Electrocardiographic prediction of coronary artery patency after thrombolytic treatment in acute myocardial infarction: use of the ST segment as a noninvasive marker. Br Heart J. 1988;60:275-80.
136. Barbash Gl, Roth A, Hod H, Miller HI, Rath S, Har-Zahav Y, et al. Rapid resolution of ST elevation and prediction of clinical outcome in patients undergoing thrombolysis with alteplase (recombinant tissue-type plasminogen activator): results of the Israeli Study of Early Intervention in Myocardial Infarction. Br Heart J. 1990;64:241-7.
137. Bossaert L, Conraads V, Pintens H. ST-segment analysis: a useful marker for reperfusion after thrombolysis with APSAC? The Belgian EMS Study Group. Eur Heart J. 1991;12:357-62.
138. Krucoff MW, Croll MA, Pope JE, Granger CB, O'Connor CM, Sigmon KM, et al. Continuous 12-lead ST segment recovery analysis in the TAMI 7 Study: performance of a noninvasive method for real time detection of failed myocardial reperfusion. Circulation. 1993;88:437-46.
139. Zabel M, Hohnloser SH, Parussel A, Just H. ST segment analysis for assessment of coronary artery patency: comparison of surface ECG and Hotter recordings. Eur Heart J. 1992;13:1619-25.
140. Topol EJ, O'Neill WW, Langburd AB, Walton JA Jr, Bourdillon PD, Bates ER, et al. A randomized, placebo-controlled thai of intravenous recombinant tissue-type plasminogen activator and emergency coronary angioplasty in patients with acute myocardial infarction. Circulation. 1987;75: 420-8.
141. Simoons ML, Arnold AE, Betriu A, de Bono DP, Col J, Dougherty FC, et al. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty. Lancet. 1988;1:197-203.
142. SWIFT trial of delayed elective intervention v conservative treatment after thrombolysis with anistreplase in acute myocardial infarction. SWIFT (Should We Intervene Following Thrombolysis?) Trial Study Group. BMJ. 1991;302: 555-60.
143. Abbottsmith CW, Topol EJ, George BS, Stack RS, Kereiakes DJ, Candela RJ, et al. Fate of patients with acute myocardial infarction with patency of the infarct-related vessel achieved with successful thrombolysis versus rescue angioplasty. J Am Coll Cardiol. 1990;16:770-8.
144. White HD, Cross DB, Williams BF, Norris RM. Safety and efficacy of repeat thrombolytic treatment after acute myocardial infarction. Br Heart J. 1990;64:177-81.
145. Barbash Gl, Hod H, Roth A, Faibel HE, Mandel Y, Miller HI, et al. Repeat infusions of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction and early recurrent myocardial ischemia. J Am Coll Cardiol. 1990;16:779-83.
146. Simoons ML, Arnout J, van den Brand M, Nyssen K, Verstraete M. Retreatment with alteplase for early signs of reocclusion after thrombolysis. The European Cooperative Study Group. Am J Cardiol. 1993;71:524-8.
147. Ellis SG, da Silva ER, Heyndrickx G, Talley JD, Cernigliaro C, Steg G, et al. Randomized comparison of rescue angioplasty with conservative management of patients with early failure of thrombolysis for acute anterior myocardial infarction. Circulation. 1994;90:2280-4.
148. Puleo PR, Meyer D, Wathen C, Tawa CB, Wheeler S, Hamburg RJ, et al. Use of a rapid assay of subforms of creatine kinase-MB to diagnose or rule out acute myocardial infarction. N Engl J Med. 1994;331:561-6.
149. Lee TH, Pearson SD, Johnson PA, Garcia TB, Weisberg MC, Guadagnoli E, et al. Failure of information as an intervention to modify clinical management. A time-series trial in patients with acute chest pain. Ann Intern Med. 1995;122:434-7.
150. Heidbuchel H, Tack J, Vanneste L, Ballet A, Ector H, Van de Werf F. Significance of arrhythmias during the first 24 hours of acute myocardial infarction treated with alteplase and effect of early administration of a beta-blocker or a bradycardic agent on their incidence. Circulation. 1994;89: 1051-9.
151. Capone RJ, Pawitan Y, el-Sherif N, Geraci TS, Handshaw K, Morganroth J, et al. Events in the cardiac arrhythmia suppression trial: baseline predictors of mortality in placebo-treated patients. J Am Coll Cardiol. 1991; 18:1434-8
152. Mark DB, Sigmon K, Topol EJ, Kereiakes DJ, Pryor DB, Candela RJ, et al.
153. Newby LK, Califf RM, Guerci A, Weaver WD, Col J, Horgan JH, et al. Early discharge in the thrombolytic era: an analysis of criteria for uncomplicated infarction from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) trial. J Am Coll Cardiol. 1996;27:625-32
154. Moss AJ. Prognosis after myocardial infarction. Am J Cardiol. 1983;52: 667-9.
155. Gottlieb S, Moss AJ, McDermott M, Eberly S. Interrelation of left ventricular ejection fraction, pulmonary congestion and outcome in acute myocardial infarction. Am J Cardiol. 1992;69:977-84.
156. Nicod P, Gilpin E, Dittrich H, Chappuis F, Ahnve S, Engler R, et al. Influence on prognosis and morbidity of left ventricular ejection fraction with and without signs of left ventricular failure after acute myocardial infarction. Am J Cardiol. 1988;61:1165-71.
157. Gadsboll N, Hoilund-Carlsen PF, Madsen EB, Marving J, Pedersen A, Lonborg-Jensen H, et al. Right and left ventricular ejection fractions: relation to one-year prognosis in acute myocardial infarction. Eur Heart J. 1987;8:1201-9.
158. Serruys PW, Simoons ML, Suryapranata H, Vermeer F, Wijns W, van den Brand M, et al. Preservation of global and regional left ventricular function after early thrombolysis in acute myocardial infarction. J Am Coll Cardiol. 1986;7:729-42.
159. Taylor GJ, Humphries JO, Mellits ED, Pitt B, Schulze RA, Griffith LS, et al. Predictors of clinical course, coronary anatomy and left ventricular function after recovery from acute myocardial infarction. Circulation. 1980; 62:960-70.
160. White HD, Norris RM, Brown MA, Takayama M, Maslowski A, Bass NM, et al. Effect of intravenous streptokmase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med. 1987;317: 850-5.
161. Gunnar RM, Bourdillon PD, Dixon DW, Fuster V, Karp RB, Kennedy JW, et al. ACC/AHA guidelines for the early management of patients with acute myocardial infarction. A report of the American College of Cardiology/ American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (subcommittee to develop guidelines for the early management of patients with acute myocardial infarction). Circulation. 1990:82:664-707.
162. Bittl JA. Indications, timing, and optimal technique for diagnostic angiography and angioplasty in acute myocardial infarction. Chest. 1991;99(4 Suppl):150S-6S.
163. Braunwald E. Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival. Should the paradigm be expanded? Circulation. 1989;78:441-4.
164. Califf RM, Granger C. TIMI IIB follow-up. Lessons for clinicians and investigators [Editorial]. Circulation. 1992;85:839-41.
165. Kulick DL, Rahimtoola SH. Risk stratification in survivors of acute myocardial infarction: routine cardiac catheterization and angiography is a reasonable approach in most patients [Editorial], Am Heart J. 1991;121:641-56.
166. Wall TC, Mark DB, Califf RM, Collins G, Burgess R, Skelton TN, et al. Prediction of early recurrent myocardial ischemia and coronary reocclusion after successful thrombolysis: a qualitative and quantitative angiographic study. Am J Cardiol. 1989;63:423-8.
167. Kleiman NS, Terrin M, Mueller H, Chaitman B, Roberts R, Knatterud GL, et al. Mechanisms of early death despite thrombolytic therapy: experience from the Thrombolysis in Myocardial Infarction Phase II (TIMI II) study. J Am Coll Cardiol. 1992;19:1129-35.
168. Muller DW, Topol EJ, Ellis SG, Woodlief LH, Sigmon KN, Kereiakes DJ, et al. Determinants of the need for early acute intervention in patients treated conservatively after thrombolytic therapy for acute myocardial infarction. TAMI-5 Study Group, J Am Coll Cardiol. 1991;18:1594-601.
169. Eisenstein EL, Newby LK, Knight JD, Shaw U, Califf RM, Topol EJ, et al. Cost avoidance through early discharge of the uncomplicated acute myocardial infarction patient [Abstract]. J Am Coll Cardiol. 1996;27:244A-5A.
170. Topol EJ, Burek K, O'Neill WW, Kewman DG, Kander NH, Shea MJ, et al. A randomized controlled trial of hospital discharge three days after myocardial infarction in the era of reperfusion. N Engl J Med. 1988;318: 1083-8.
171. Pryor DB, Hindman MC, Wagner GS, Califf RM, Rhoads MK, Rosati RA. Early discharge after acute myocardial infarction. Ann Intern Med. 1983; 99:528-38.
172. Goldman L, Cook EF, Lee TH, Rouan OW, Weisberg MC. Prospective validation of a simple algorithm to predict complications requiring intensive care among emergency room patients with acute chest pain [Abstract]. Clin Res. 1989;37:524A.
173. Sanz G, Betriu A, Oiler G, Matas M, Magrina J, Pare C, et al. Feasibility of early discharge after acute Q wave myocardial infarction in patients not receiving thrombolytic treatment. J Am Coll Cardiol. 1993;22:1795-801.
174. Shaw LJ, Pieper K, Peterson ED, Eagle KA, Wagner GS, Califf RM. Optimization of resources by efficient use of readily available simple clinical measures in a high-risk post-myocardial infarction population. Presented at the 13th Annual Meeting of the Association for Health Service Research, Atlanta, GA, June 9-11, 1996.
175. Schreiber T, Marsalese D, Griffin J, Donohue B, Sampaolesi A, Constantini C, et al. Identification of ultra low-risk patients following primary angioplasty for acute myocardial infarction [Abstract], J Am Coif Cardiol. 1996;27:83A.
176. Peterson ED, Jollis JG, DeLong ER, Stafford JA, Muhlbaier LH, Shaw U, et al. National patterns of post-Mi noninvasive testing in the elderly: results in 190,237 patients [Abstract]. Circulation. 1996;94:I-441.
177. Mark DB, Granger CB, Ellis SG, Phillips HR, Knight D, Davidson-Ray L, et al. Costs of direct angioplasty versus thrombolysis for acute myocardial infarction: results from the GUSTO II randomized trial [Abstract]. Circulation. 1996:94:1-168.
178. Charles ED, Rogers WJ, Reeder GS, Chesebro JH, Papapietro SE. Economic advantages of a conservative strategy for AMI management: rt-PA without obligatory PTCA [Abstract]. J Am Coll Cardiol. 1989;13:152A.
179. Mark DB. Medical economics and health policy issues for interventional cardiology. In: Topol EJ, ed Textbook of Interventional Cardiology. 2d ed. Philadelphia: WB Saunders; 1994:1323-53
180. Risk stratification and survival after myocardial infarction Multicenter Post-Infarction Research Group. N Engl J Med 1983;309:321-6.
181. Sanz G, Castaner A, Betriu A, Magrina J, Roig E, Coll S, et al. Determinants of prognosis in survivors of myocardial infarction, a prospective clinical angiographie study. N Engl J Med. 1982;306:1065-70.
182. Harris P. The problem of defining heart failure, Cardiovasc Drugs Ther. 1994;8:447-52.
183. Greenberg H, McMaster P, Dwyer EM Jr. Left ventricular dysfunction after acute myocardial infarction: results of a prospective multicenter study. J Am Coll Cardiol 1984;4:867-74.
184. Volpi A, De Vita C, Franzosi MG, Geraci E, Maggioni AP, Mauri F, et al. Determinants of 6-month mortality in survivors of myocardial infarction after thrombolysis. Results of the GI551-2 data base. The Ad hoc Working Group of the Gruppo Italiano per lo Studio della Soprawivenza nell'lnfarto Miocardio (GISSD-2 Data Base. Circulation. 1993;88:416-29
185. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopnl on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-77.
186. Konstam MA, Kronenberg MW, Rousseau MF, Udelson JE, Melin J, Stewart D, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation m patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators. Circulation. 1993;88(5 Pt 1):2277-83.
187. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet. 1995;345:669-85.
188. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS1). Lancet. 1995;345:686-7.
189. Anderson WD, Wagner NB, Lee KL, White RD, Yuschak J, Behar VS, et al. Evaluation of a QRS scoring system for estimating myocardial infarct size. VI: Identification of screening criteria for non-acute myocardial infarcts. Am J Cardiol. 1988;61:729-33.
190. Hamby Rl, Murphy D, Hoffman I. Clinical predictability of left ventricular function post myocardial infarction from the electrocardiogram. Am Heart J. 1985;109:338-42.
191. Silver MT, Rose GA, Paul SD, O'Donnell CI, O'Gara PT, Eagle KA. A clinical rule to predict preserved left ventricular ejection fraction in patients after myocardial infarction. Ann Intern Med. 1994;121:750-6.
192. Corbett JR, Dehmer GJ, Lewis SE, Woodward W, Henderson E, Parkey RW, et al. The prognostic value of submaximal exercise testing with radionuclide ventriculography before hospital discharge in patients with recent myocardtal infarction. Circulation. 1981;64:535-44,
193. White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation. 1987;76:44-51.
194. Bouwels L, Hertzberger D. How long should high-risk patients with acute anterior wall myocardial infarction be monitored? Int J Cardiol. 1992:35. 355-64.
195. McComb JM, Gold HK, Leinbach RC, Newell JB, Ruskin JN, Garan H. Electrically induced ventricular arrhythmias in acute myocardial infarction treated with thrombolytic agents. Am J Cardiol. 1988;62:186-91.
196. Kuchar DL, Thorburn CW, Sammel NL. Late potentials detected after myocardial infarction: natural history and prognostic significance. Circulation. 1986;74:1280-9.
197. Willems AR, Tijssen JG, van Capelle FJ, Kingma JH, Hauer RN, Vermeulen FE, et al. Determinants of prognosis in symptomatic ventricular tachycardia or ventricular fibrillation late after myocardial infarction. The Dutch Ventricular Tachycardia Study Group of the Interuniversity Cardiology Institute of The Netherlands. J Am Coll Cardiol. 1990;16:521-30.
198. Pedretti R, Etro MD, Laporta A, Braga SS, Caru B, Prediction of late arrhythmic events after acute myocardial infarction from combined use of noninvasive prognostic variables and inducibility of sustained monomorphic ventricular tachycardia. Am J Cardiol. 1993;71:1131-41.
199. Vaage-Nilsen M, Rasmussen V, Hansen JF, Hagerup L, Sorensen MB, Bjergaard OP, et al. Effect of verapamil on ischemia and ventricular arrhythmias after an acute myocardial infarction: prognostic implications. The Danish Verapamil Infarction Trial II Study Group. J Cardiovasc Pharmacol. 1991;18:S26-9.
200. Maggioni AP, Zuanetti G, Franzosi MG, Rovelli F, Santoro E, Staszewsky L, et al. Prevalence and prognostic significance of ventricular arrhythmias after acute myocardial infarction in the fibrinolytic era. GISSI-2 results. Circulation. 1993;87:312-22.
201. Bigger JT Jr, Fleiss JL, Rolnitzky LM. Prevalence, characteristics and significance of ventricular tachycardia detected by 24-hour continuous electrocardiographic recordings in the late hospital phase of acute myocardial infarction. Am J Cardiol 1986;58:1151-60.
202. Kostis JB, Byington R, Friedman LM, Goldstein S, Furberg C. Prognostic significance of ventricular ectopic activity in survivors of acute myocardial infarction. J Am Coll Cardiol. 1987;10:231-42.
203. Zhang YZ, Wang SW, Hu DY, Zhu GY. Prediction of life threatening arrhythmia in patients after myocardial infarction by late potentials, ejection fraction and Holter monitoring. Jpn Heart J. 1992;33:15-23.
204. Candell-Riera J, Permanyer-Miralda G, Castell J, Rius-Davi A, Domingo E, Alvarez-Aunon E, et al. Uncomplicated first myocardial infarction: strategy for comprehensive prognostic studies. J Am Coll Cardiol. 1991;18:1207-19.
205. Currie P, Saltissi S. Transient myocardial ischaemia after acute myocardial infarction does not induce ventricular arrhythmias. Br Heart J. 1993;69: 303-7.
206. Connolly SJ, Cairns JA. Prevalence and predictors of ventricular premature complexes in survivors of acute myocardial infarction. CAMIAT Pilot Study Group. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial. Am J Cardiol. 1992;69:408-11.
207. Eldar M, Sievner Z, Goldbourt U, Reicher-Reiss H, Kaplinsky E, Behar S. Primary ventricular tachycardia in acute myocardial infarction: clinical characteristics and mortality. The SPRINT Study Group. Ann Intern Med. 1992;117:31-6.
208. Behar S, Rabinowitz B, Zion M, Reicher-Reiss H, Kaplinsky E, Abinader E, et al. Immediate and long-term prognostic significance of a first anterior versus first inferior wall Q-wave acute myocardial infarction. Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT) Study Group. Am J Cardiol. 1993;72:1366-70.
209. McClements BM, Adgey AA. Value of signal-averaged electrocardiography, radionuclide ventriculography, Holter monitoring and clinical variables for prediction of arrhythmic events in survivors of acute myocardial infarction in the thrombolytic era. J Am Coll Cardiol. 1993;21:1419-27.
210. Steinberg JS, Regan A, Sciacca RR, Bigger JT Jr, Fleiss JL. Predicting arrhythmic events after acute rnyocardial infarction using the signal-averaged electrocardiogram. Am J Cardiol. 1992;69:13-21.
211. Willems JL, Willems RJ, Willems GM, Arnold AE, Van de Werf F, Verstraete M. Significance of initial ST segment elevation and depression for the management of thrombolytic therapy in acute myocardial infarction. European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator. Circulation. 1990;82:1147-58.
212. Kowey PR, Friehling T, Meister SG, Engel TR. Late induction of tachycardia in patients with ventricular fibrillation associated with acute myocardial infarction. J Am Coll Cardiol. 1984;3:690-5.
213. van Hemel NM, Kingma JH, Defauw JA, Vermeulen FE, Mast EG, Ernst JM, et al. Left ventricular segmental wall motion score as a criterion for selecting patients for direct surgery in the treatment of postinfarction ventricular tachycardia. Eur Heart J. 1989;10:304-15.
214. Aguirre FV, Kern MJ, Hsia J, Serota H, Janosik D, Greenwalt T, et al. Importance of myocardial infarct artery patency on the prevalence of ventricular arrhythmia and late potentials after thrombolysis in acute myocardial infarction. Am J Cardiol. 1991;68:1410-6.
215. Hong M, Peter T, Peters W, Wang FZ, Xiu YX, Vaughn C, et al. Relation between acute ventricular arrhythmias, ventricular late potentials and mortality in acute rnyocardial infarction. Am J Cardiol. 1991;68:1403-9.
216. Denes P, el-Sherif N, Katz R, Capone R, Carlson M, Mitchell LB, et al. Prognostic significance of signal-averaged electrocardiogram after thrombolytic therapy and/or angioplasty during acute myocardial infarction (CAST substudy). Cardiac Arrhythmia Suppression Trial (CAST) SAECG Substudy Investigators. Am J Cardiol. 1994;74:216-20.
217. Gomes JA, Winters SL, Stewart D, Horowitz S, Milner M, Barreca P. A new noninvasive index to predict sustained ventricular tachycardia and sudden death in the first year after myocardial infarction: based on signalaveraged electrocardiogram, radionuclide ejection fraction and Holter monitoring. J Am Coll Cardiol. 1987;10:349-57.
218. Hohnloser SH, Franck P, Klingenheben T, Zabel M, Just H. Open infarct artery, late potentials, and other prognostic factors in patients after acute myocardial infarction in the thrombolytic era. A prospective trial. Circulation. 1994;90:1747-56.
219. Zaman AG, Morris JL, Smyllie JH, Cowan JC. Late potentials and ventricular enlargement after myocardial infarction. A new role for high-resolution electrocardiography? Circulation. 1993;88:905-14.
220. Kleiger RE, Miller JP, Bigger JT Jr, Moss AJ. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Arn J Cardiol. 1987;59:256-62.
221. Farrell TG, Odemuyiwa O, Bashir Y, Cripps TR, Malik M, Ward DE, et al. Prognostic value of baroreflex sensitivity testing after acute myocardial infarction. Br Heart J. 1992;67:129-37.
222. La Rovere MT, Montara A, Specchia G, Schwartz PJ. Myocardial infarction and baroreflex sensitivity. Clinical studies. G Ital Cardiol. 1992;22:639-45.
223. Rich MW, Saini JS, Kleiger RE, Carney RM, teVelde A, Freedland KE. Correlation of heart rate variability with clinical and angiographic variables and late mortality after coronary angiography. Am J Cardiol. 1988;62(10 Pt 1):714-7.
224. Zbilut JP, Lawson L. Decreased heart rate variability in significant cardiac events. Cm Care Med. 1988;16:64-6.
225. Schwartz PJ, La Rovere MT, Vanoli E. Autonomic nervous system and sudden cardiac death. Experimental basis and clinical observations for postmyocardial infarction risk stratification. Circulation. 1992;85(1 Suppl):177-91.
226. Zabel M, Klingenheben T, Hohnloser SH. Changes in autonomic tone following thrombolytic therapy for acute myocardial infarction: assessment by analysis of heart rate variability. J Cardiovasc Electrophysiol. 1994;5: 211-8
227. Singh N, Mironov D, Armstrong PW, Ross AM, Langer A. Heart rate variability assessment early after acute myocardial infarction. Pathophysiological and prognostic correlates. GUSTO ECG Substudy Investigators. Global Utilization of Streptokmase and TPA for Occluded Arteries. Circulation. 1996;93:1388-95
228. Hamer A, Vohra J, Hunt D, Sloman G. Prediction of sudden death by electrophysiologic studies in high risk patients surviving acute myocardial infarction. Am J Cardiol. 1989;50:223-9.
229. Marchlinski FE, Buxton AE, Waxton HL, Josephson ME. Identifying patients at risk of sudden death after myocardial infarction: value of the response to programmed stimulation, degree of ventricular ectopic activity and severity of left ventricular dysfunction. Am J Cardiol. 1983;52:1190-6.
230. Richards DA, Byth K, ROSS DL, Uther JB. What is the best predictor of spontaneous ventricular tachycardia and sudden death after myocardial infarction? Circulation. 1991;83:756-63.
231. Santarelli P, Bellocci F, Loperfido F, Mazzari M, Mongiardo R, Montenero AS, et al. Ventricular arrhythmia induced by programmed ventricular stimulation after acute myocardial infarction. Am J Cardiol. 1985;55: 391-4.
232. Roy D, Marchand E, Theroux P, Waters DD, Pelletier GB, Bourassa MG. Programmed ventricular stimulation in survivors of an acute myocardial infarction. Circulation. 1985;72:487-94.
233. Waspe LE, Seinfeld D, Ferrick A, Kim SG, Matos JA, Fisher JD. Prediction of sudden death and spontaneous ventricular tachycardia in survivors of complicated myocardial infarction: value of the response to programmed stimulation using a maximum of three ventricular extrastimuli. J Am Coll Cardiol. 1985;5:1292-301.
234. Gonzalez R, Arriagada D, Corbalan R, Chamorro G, Fajuri A, Rodriguez JA. Role of programmed electrical stimulation of the heart in risk stratification post-myocardial infarction. Pacing Clin Electrophysiol. 1988;11: 283-8.
235. Denniss AR, Baaijens H, Cody DV, Richards DA, Russell PA, Young AA, et al. Value of programmed stimulation and exercise testing in predicting one-year mortality after acute myocardial infarction. Am J Cardiol. 1985; 56:213-20.
236. Denniss AR, Richards DA, Cody DV, Russell PA, Young AA, Cooper MJ, et al. Prognostic significance of ventricular tachycardia and fibrillation induced at programmed stimulation and delayed potentials detected on the signal-averaged electrocardiograms of survivors of acute myocardial infarction. Circulation. 1986;74:731-45.
237. Cripps T, Bennett ED, Camm AJ, Ward DE. Indudbility of sustained monomorphic ventricular tachycardia as a prognostic indicator in survivors of recent myocardial infarction: a prospective evaluation in relation to other prognostic variables. J Am Coll Cardiol. 1989;14:289-96.
238. Bhandari AK, Hong R, Kotlewski A, Mclntosh N, Au P, Sankoorikal A, et al. Prognostic significance of programmed ventricular stimulation in survivors of acute myocardial infarction. Br Heart J. 1989;61:410-6.
239. Richards DA, Cody DV, Denniss AR, Russell PA, Young AA, Uther JB. Ventricular electrical instability: a predictor of death after myocardial infarction. Am J Cardiol. 1983;51:75-80.
240. Krone RJ, Friedman E, Thanavaro S, Miller JP, Kleiger RE, Oliver GC. Long-term prognosis after first Q-wave (transmural) or non-Q-wave (nontransmural) myocardial infarction: analysis of 593 patients. Am J Cardiol. 1983;52:234-9.
241. Klein J, Froelicher VF, Detrano R, Dubach P, Yen R. Does the rest electrocardiogram after myocardiai infarction determine the predictive value of exercise-induced ST depression? A 2 year follow-up study in a veteran population. J Am Coll Cardiol, 1989;14:305-11.
242. Sutton JM, Topol EJ. Significance of a negative exercise thallium test in the presence of a critical residual stenosis after thrombolysis for acute myocardial infarction. Circulation. 1991;83:1278-86.
243. Mahmarian JJ, Pratt CM, Boyce TM, Verani MS. The variable extent of jeopardized myocardium in patients with single vessel coronary artery disease: quantification by thallium-201 single photon emission computed tomography. J Am Coll Cardiol. 1991;17:355-62.
244. Patterson RE, Horowitz SF, Eng C, Meiler J, Goldsmith SJ, Pichard AD, et al. Can noninvasive exercise test criteria identify patients with left main or 3-vessel coronary disease after a first myocardial infarction? Am J Cardiol. 1983;51:361-72.
245. Pirelli S, Inglese E, Suppa M, Corrada E, Campolo L. Dipyndamolethallium 201 sontigraphy in the early post-infarction period. (Safety and accuracy in predicting the extent of coronary disease and future recurrence of angina in patients suffering from their first myocardial infarction). Eur Heart J. 1988;9:1324-31.
246. Valette H, Bourguignon MH, Le Guludec D, Merlet P, Dove PJ, Kiger JP, et al. ECG gated thallium 201 myocardial images: value in detecting multivessel disease in patients on anti anginal therapy 1-3 months after myocardial infarction. Eur J Nucl Med. 1988;13:551-6.
247. Smeets JP, Rigo P, Legrand V, Chevigne M, Hastir F, Kulbertus HE. Prognostic value of thallium-201 stress myocardial scintigraphy with exercise ECG after myocardial infarction. Cardiology. 1981;68(Suppl 2):67-70.
248. Gibson RS, Watson DD, Craddock GB, Crampton RS, Kaiser DL, Denny MJ, et al. Prediction of cardiac events after uncomplicated myocardial infarction: a prospective study comparing predischarge exercise thallium-201 scintigraphy and coronary angiography. Circulation. 1983,68:321-36.
249. Gibson RS, Beller GA, Gheorghiade M, Nygaard TW, Watson DD, Huey BL, et al. The prevalence and clinical significance of residual myocardial ischemia 2 weeks after uncomplicated non-Q wave infarction: a prospective natural history study. Circulation 1986;73.1186-98
250. Griffin BP, Shah PK, Diamond GA, Berman DS, Ferguson JG. Incremental prognostic accuracy of clinical, radionuclide and hemodynamic data in acute myocardial infarction Am J Cardiol. 1991;68:707-12.
251. Nicod P, Corbett JR. Firth BG, Lewis SE, Rude RE, Huxley R, et al. Prognostic value of resting and submaximal exercise radionuclide ventriculography after acute myocardial infarction in high-risk patients with single and multivessel disease. Am J Cardiol. 1983;52:30-6.
252. Michels KB, Yusuf S. Does PTCA in acute myocardial infarction affect mortality and reinfarction rates? A quantitative overview (meta-analysis) of the randomized clinical trials Circulation. 1995;91:476-85
253. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. Circulation. 1994;89:1545-56.
254. Mark DB, Naylor CD, Hlatky MA, Califf RM, Topol EJ, Granger CB. et al. Use of medical resources and quality of life after acute myocardial infarction in Canada and the United States. N Engl J Med. 1994;331:1130-5.
255. Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet. 1994;344:563-70.
256. Mark DB, Nelson CL, Califf RM, Harrell FE Jr. Lee KL, Jones RH, et al. Continuing evolution of therapy for coronary artery disease. Initial results from the era of coronary angioplasty. Circulation. 1994;89:2015-25.
257. Califf RM, Harrell FE Jr, Lee KL, Rankin JS, Hlatky MA, Mark DB, et al. The evolution of medical and surgical therapy for coronary artery disease. A 15-year perspective. JAMA. 1989;261:2077-86.
258. Siegel D, Grady D, Browner WS, Hulley SB. Risk factor modification after myocardial infarction. Ann Intern Med. 1988;109:213-8.
259. Yusuf S, Lessem J, Jha P, Lonn E. Primary and secondary prevention of myocardial infarction and strokes: an update of randomly allocated, controlled trials. J Hypertens Suppl. 1993;11:S61-73.
260. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-9.
261. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269: 3015-23.
262. American Heart Association. Heart and Stroke Facts. Dallas: American Heart Assoc; 1994.
263. Krumholz HM, Cohen BJ, Tsevat J, Pasternak RC, Weinstein MC. Cost-effectiveness of a smoking cessation program after myocardial infarction. J Am Coll Cardiol. 1993;22:1697-702.
264. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 1986;2:533-7.
265. Meade TW, Wilkes HC, Stirling Y, Brennan PJ, Kelleher C, Browne W. Randomized controlled trial of low dose warfarin in the primary prevention of ischaemic heart disease in men at high risk: design and pilot study. Eur Heart J. 1988;9:836-43.
266. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016-37.
267. Sullivan JM, Vander Zwaag R, Hughes JP, Maddock V, Kroetz FW, Ramanathan KB, et al. Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women. Arch Intern Med 1990;150: 2557-62.
268. Case RB, Moss AJ, Case N, McDermott M, Eberly S. Living alone after myocardial infarction. Impact on prognosis. JAMA. 1992;267:515-9.
269. Frasure-Smith N, Lesperance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation. 1995;91:999-1005.
270. Williams RB, Barefoot JC, Califf RM, Haney TL, Saunders WB, Pryor DB, et al. Prognostic importance of social and economic resources among medically treated patients with angiographically documented coronary artery disease. JAMA. 1992;267:520-4.
271. Friedman M, Thoresen CE, Gill JJ, Ulmer D, Powell LH, Price VA, et al. Alteration of type A behavior and its effect on cardiac recurrences in post myocardial infarction patients: summary results of the recurrent coronary prevention project. Am Heart J. 1986;112:653-65.
272. Blumenthal JA, Bradley W, Dimsdale JE, Kasl SV, Powell LH. Taylor CB. Task Force III: Assessment of psychological status in patients with ischemic heart disease. J Am Coll Cardiol. 1989;14:1034-42.
273. O'Connor GT, Buring JE, Yusuf S, Goldhaber SZ, Olmstead EM, Paffenbarger RS Jr, et al. An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation. 1989;80:234-44.
274. Oldridge N, Guyatt G, Jones N, Crowe J, Singer J, Feeny D, et al. Effects on quality of life with comprehensive rehabilitation after acute myocardial infarction. Am J Cardiol. 1991;67:1084-9.
275. Oldridge N, Furlong W, Feeny D, Torrance G, Guyatt G, Crowe J, et al. Economic evaluation of cardiac rehabilitation soon after acute myocardial infarction. Am J Cardiol. 1993;72:154-61.
276. Collaborative overview of randomised trials of antiplatelet therapy - II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists' Collaboration. BMJ. 1994;308:159-68.
277. Lotto A, Colombo A, Talarico G, Fratianni G, Lettino M. Heparin and secondary prevention of acute myocardtal infarction. Haemostasis. 1990; 20(Suppi 1): 132-41.
278. Hampton JR. Secondary prevention of acute myocardial infarction with beta-blocking agents and calcium antagonists. Am J Cardiol. 1990;66:3C-8C.
279. Olsson G, Wikstrand J, Warnold I, Manger Cats V, Me Boy le D, Herlitz J, et al. Metoprolol-induced reduction in postinfarction mortality: pooled results from five double-blind randomized trials. Eur Heart J. 1992;13:28-32.
280. Ellerbeck EF, Jencks SF, Radford MJ, Kresowik TF, Craig AS, Gold JA, et al. Quality of care for Medicare patients with acute myocardial infarction. A four-state pilot study from the Cooperative Cardiovascular Project. JAMA. 1995;273:1509-14.